Covaxin 77.8% effective against Covid-19 in Lancet study
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Monday
January 30, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
MONDAY, JANUARY 30, 2023
Covaxin 77.8% effective against Covid-19 in Lancet study

Coronavirus chronicle

Hindustan Times
12 November, 2021, 09:25 am
Last modified: 12 November, 2021, 09:30 am

Related News

  • Indian drug regulator okays Covaxin for 6-12 year olds, Corbevax for 5-12 bracket
  • Bharat Biotech on WHO's Covaxin supply suspension: No impact on efficacy, safety
  • WHO suspends Covaxin supplies under UN procurement
  • India gives conditional market nod for Covishield and Covaxin
  • India's Bharat Biotech says Covaxin booster shot neutralises Omicron

Covaxin 77.8% effective against Covid-19 in Lancet study

According to the study, efficacy data of the whole virion-inactivated vaccine further demonstrates 63.6% protection against asymptomatic disease and 65.2% protection against the B.1.617.2 Delta variant

Hindustan Times
12 November, 2021, 09:25 am
Last modified: 12 November, 2021, 09:30 am
Covaxin 77.8% effective against Covid-19 in Lancet study

Analysis data on the safety and efficacy of Bharat Biotech's vaccine against Covid-19, Covaxin, following its Phase 3 clinical trials, has been peer-reviewed and published in the medical journal, The Lancet.

It came four months after the India-based company demonstrated, in a published pre-print study, that its vaccine against the coronavirus disease had 77.8% efficacy against symptomatic cases and 93.4% against severe symptomatic cases.

According to the study, efficacy data of the whole virion-inactivated vaccine further demonstrates 63.6% protection against asymptomatic disease and 65.2% protection against the B.1.617.2 Delta variant.

"The Lancet peer review confirms the efficacy analysis that demonstrates Covaxin to be effective against Covid-19. Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from Phase 3 clinical trials against the Delta variant at 65.2%," said Bharat Biotech in a statement after The Lancet published the study on Friday.

The efficacy analysis was done after the evaluation of 130 confirmed Covid-19 cases, with 24 observed in the vaccine group as against 106 in the placebo group.

Bharat Biotech developed the anti-Covid jab in partnership with the Indian Council of Medical Research (ICMR) and the National Institute of Virology in Pune.

The company had received strains of Sars-CoV-2 isolated by the Indian government's apex virology laboratory in March 2020.

"The peer review of Covaxin's Phase 3 clinical trial data in The Lancet, an authoritative voice in global medicine, validates our commitment to data transparency and meeting the stringent peer review standards of world-leading medical journals," Krishna Ella, chairman and managing director of Bharat Biotech, said in a statement.

"The data from our product development and clinical trials has been published in 10 peer-reviewed journals, making Covaxin one of the most highly published Covid-19 vaccines in the world. This accomplishment reflects the undeterred commitment by my team members at Bharat Biotech, our public partners, the ICMR, the National Institute of Virology and the trust imposed by our trial participants who made this happen," Ella said.

The Phase 3 trial efficacy and safety study involved 25,800 volunteers across 25 sites in India. According to the company, Covaxin was well tolerated and the Data Safety Monitoring Board didn't report any safety concerns related to the vaccine.

"The safety profile of Covaxin is now well established based on inactivated vaccines technology, and in large part due to the extensive 25-year safety track record of Bharat Biotech's vero cell manufacturing platform," the company said in its statement.

On November 3, the vaccine was granted emergency-use listing by the World Health Organization (WHO), giving various countries to expedite their own regulatory nods to import Covaxin vials.

Balram Bhargava, director general of the ICMR, said, "Following successful isolation of the Sars-CoV-2 virus at the ICMR-National Institute of Virology in Pune, the ICMR and Bharat Biotech embarked upon one of the most successful public-private partnerships to develop the virus isolate into an effective Covid-19 vaccine.

"I am delighted to see that the Phase 3 efficacy data has also been published in The Lancet, one of the most reputed journals worldwide. It speaks highly about the strong position of Covaxin among other global front-runners [with respect to] Covid-19 vaccines. The bench-to-bedside journey of Covaxin in less than 10 months showcases the immense strength of Atmanirbhar Bharat along with the Indian academia and industry in fighting against the odds and carving a niche in the global community."

According to the company, its emergency-use authorisation application is in process in at least 50 countries.

"With more than 150 million doses manufactured and supplied, and with an excellent safety and efficacy profile, Covaxin is a major contributor to the global fight against the Covid-19 pandemic. Covaxin is currently being evaluated in controlled clinical trials among children aged 2-18, with results available during Q4 this year. Bharat Biotech is poised to achieve its goal of an annualised capacity of 1 billion doses of Covaxin by the end of 2021," the company said in its statement.

Top News

COVAXIN

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Photo: Bloomberg
    Adani rout hits $71 billion as fight with Hindenburg intensifies
  • Prime Minister Sheikh Hasina. Sketch: TBS
    Continued democracy helps rapid development: PM Hasina
  • Representational image. Photo: Mumit M/ TBS
    Stocks slide down for second consecutive day

MOST VIEWED

  • A nurse prepares a shot for Jonathan Halter as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo
    Covid remains a public health emergency, says WHO
  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs
  • Photo: Collected
    India launches world’s 1st intranasal Covid vaccine
  • A vial of the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot
  •  A medical worker checks the IV drip treatment of a patient lying on a bed in the emergency department of a hospital, amid the coronavirus disease (COVID-19) outbreak in Shanghai, China, January 5, 2023. REUTERS/Staff
    China says Covid deaths down by nearly 80 percent

Related News

  • Indian drug regulator okays Covaxin for 6-12 year olds, Corbevax for 5-12 bracket
  • Bharat Biotech on WHO's Covaxin supply suspension: No impact on efficacy, safety
  • WHO suspends Covaxin supplies under UN procurement
  • India gives conditional market nod for Covishield and Covaxin
  • India's Bharat Biotech says Covaxin booster shot neutralises Omicron

Features

Photo: Courtesy

The Hawkers: Where minimalism meets motifs

7h | Brands
TBS illustration

Where do Shariah-compliant mutual funds stand in Bangladesh

5h | Panorama
Sketch: TBS

A subsidy war without winners

5h | Panorama
Photo: Collected

Oppo Reno 8T first look revealed!

6h | Brands

More Videos from TBS

Youths at the invitation of TBS

Youths at the invitation of TBS

1h | TBS Graduates
Predicting next three years is tough- Kutubuddin Ahmed

Predicting next three years is tough- Kutubuddin Ahmed

2h | TBS Round Table
Pakistan plunges into economic mess

Pakistan plunges into economic mess

4h | TBS World
Shahrukh's 'Pathaan' has been making records ever since its release

Shahrukh's 'Pathaan' has been making records ever since its release

5h | TBS Entertainment

Most Read

1
Picture: Collected
Bangladesh

US Embassy condemns recent incidents of visa fraud

2
Illustration: TBS
Banking

16 banks at risk of capital shortfall if top 3 borrowers default

3
Bapex calls candidates for job test 9 years after advert!
Bangladesh

Bapex calls candidates for job test 9 years after advert!

4
Photo: Collected
Splash

Hansal Mehta responds as Twitter user calls him 'shameless' for making Faraaz

5
A frozen Beyond Burger plant-based patty. Photographer: AKIRA for Bloomberg Businessweek
Bloomberg Special

Fake meat was supposed to save the world. It became just another fad

6
Representational Image
Banking

Cash-strapped Islami, Al-Arafah and National turn to Sonali Bank for costly fund

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]